medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2020, Number 3

<< Back Next >>

Rev Mex Urol 2020; 80 (3)

Risk factors for biochemical relapse in patients with prostate cancer treated by cryoablation at a Mexican referral center

Cervantes-Palma C, Martínez-Alonso IA, Bravo-Castro EI, Díaz-Gómez C, Torres-Gómez JJ, Campos-Salcedo JG

Language: Spanish
References: 20
Page: 1-10
PDF size: 174.44 Kb.


ABSTRACT

Objective: To determine the risk factors for biochemical relapse (BR) in patients with prostate cancer (PCa) treated by cryoablation.
Materials and methods: A retrospective, cross-sectional, analytic study was conducted on 36 patients with PCa, treated by cryoablation at the Hospital Central Militar, within the time frame of January 2012 to October 2018. BR was determined utilizing the Phoenix criterion. A bivariate analysis was carried out and the odds ratio (OR) was calculated for different variables.
Results: Mean follow-up duration was 32.1 months, mean PSA nadir was 2.07 ng/mL after cryoablation, with a mean of 4.92 months for reaching that PSA level. Nine patients developed BR. In the risk analysis, only the PSA nadir at its cutoff value ›0.8 ng/mL was identified as a risk factor for BR (OR 8.3, 95% CI, 1.40 – 49.06; p=0.01).
Discussion: Ours is the first national study that identified the PSA nadir as a risk factor for BR in patients with PCa treated by cryoablation.
Conclusions: In the present study, the PSA nadir was a risk factor for BR in patients with PCa treated by cryoablation, upon demonstrating an 8.3-fold higher risk for the development of BR after treatment.


REFERENCES

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-386. doi: https://doi.org/10.1002/ijc.29210

  2. Sierra MS, Soerjomataram I, Forman D. Prostate cancer burden in Central and South America. Cancer Epidemiol. 2016 Sep;44 Suppl 1:S131–40. doi: https://doi.org/10.1016/j. canep.2016.06.010

  3. van der Poel HG, van den Bergh RCN, Briers E, Cornford P, Govorov A, Henry AM, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol. 2018;74(1):84–91. doi: https://doi.org/10.1016/j.eururo.2018.01.001

  4. Valerio M, Cerantola Y, Eggener SE, Lepor H, Polascik TJ, Villers A, et al. New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. Eur Urol. 2017;71(1):17–34. doi: https://doi. org/10.1016/j.eururo.2016.08.044

  5. Han K-R, Belldegrun AS. Third-generation cryosurgery for primary and recurrent prostate cancer. BJU Int. 2004 Jan;93(1):14– 8. doi: https://doi.org/10.1111/j.1464- 410x.2004.04547.x

  6. Hubosky SG, Fabrizio MD, Schellhammer PF, Barone BB, Tepera CM, Given RW. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life. J Endourol. 2007 Dec;21(12):1521–31. doi: https://doi.org/10.1089/end.2007.9875

  7. Hernández-Martínez G, Serrano-Brambila EA, Sierra-Ramírez JA. Crioterapia prostática para cáncer de próstata a 10 años de experiencia internacional. Resultados oncológicos. Mesa Directiva Nacional 2017-2019. 2017;32(3):114.

  8. Castillo-De Lira HH, Venegas-Ocampo PJ, Robles-Scott MA, Gutiérrez-Ochoa J, Landa- Soler M, Xochipiltécatl-Muñoz JD. Efectividad de la crioterapia para el cáncer de próstata confinado en el órgano. Estudio Comparativo. Rev Mex Urol. 2010;70(1):6–10.

  9. Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology. 2002 Aug;60(2 Suppl 1):3–11. doi: https://doi. org/10.1016/s0090-4295(02)01678-3

  10. Long JP, Bahn D, Lee F, Shinohara K, Chinn DO, Macaluso JN. Five-year retrospective, multi-institutional pooled analysis of cancerrelated outcomes after cryosurgical ablation of the prostate. Urology. 2001 Mar;57(3):518– 23. doi: https://doi.org/10.1016/s0090- 4295(00)01060-8

  11. Rodríguez SA, Arias Fúnez F, Bueno Bravo C, Rodríguez-Patrón Rodríguez R, Sanz Mayayo E, Palacios VH, et al. Cryotherapy for primary treatment of prostate cancer: intermediate term results of a prospective study from a single institution. Prostate Cancer. 2014;2014:571576. doi: https://doi.org/10.1155/2014/571576

  12. Cho S, Kang SH. Current status of cryotherapy for prostate and kidney cancer. Korean J Urol. 2014 Dec;55(12):780–8. doi: https://doi. org/10.4111/kju.2014.55.12.780

  13. Ritch CR, Katz AE. Prostate cryotherapy: current status. Curr Opin Urol. 2009 Mar;19(2):177–81. doi: https://doi.org/10.1097/ mou.0b013e32831e16ce

  14. Levy DA, Jones JS. Impact of prostate gland volume on cryoablation prostate-specific antigen outcomes. Urology. 2011 Apr;77(4):994–8. doi: https://doi.org/10.1016/j.urology.2010.08.010

  15. Spiess PE, Levy DA, Mouraviev V, Pisters LL, Jones JS. Predictors of biochemical failure in patients undergoing prostate whole-gland salvage cryotherapy: a novel risk stratification model. BJU Int. 2013 Aug;112(4):E256-261. doi: https:// doi.org/10.1111/j.1464-410X.2012.11695.x

  16. Sverrisson EF, Nguyen H, Kim T, Pow- Sang JM. Primary cryosurgery for clinically localized prostate cancer--do perioperative tumor characteristics correlate with posttreatment biopsy results? Urology. 2014 Feb;83(2):376–8. doi: https://doi.org/10.1016/j. urology.2013.10.018

  17. Jones JS, Rewcastle JC. Primary cryoablation for Gleason 8, 9, or 10 localized prostate cancer: Biochemical and local control outcomes from the Cryo OnLine database registry. Indian J Urol. 2008 Oct;24(4):490–3. doi: https://doi. org/10.4103/0970-1591.44254

  18. Levy DA, Ross AE, ElShafei A, Krishnan N, Hatem A, Jones JS. Definition of biochemical success following primary whole gland prostate cryoablation. J Urol. 2014 Nov;192(5):1380–4. doi: https://doi.org/10.1016/j.juro.2014.05.003

  19. Caso JR, Tsivian M, Mouraviev V, Polascik TJ. Predicting biopsy-proven prostate cancer recurrence following cryosurgery. Urol Oncol. 2012 Aug;30(4):391–5. doi: https://doi. org/10.1016/j.urolonc.2010.04.001

  20. Liu YY, Chiang PH, Chuang YC, Lee WC, Cheng YT, Wang HJ. Predictors of prostatespecific antigen biochemical recurrence in patients undergoing primary whole-gland prostate cryoablation. Ann Surg Oncol. 2015 May;22(5):1612–7. doi: https://doi. org/10.1245/s10434-014-3942-9.




2020     |     www.medigraphic.com